Modeling The Economic Burden Of Adult Vaccine-Preventable Diseases In The United States

Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance

(2015) Matthew R Moore et al.   LANCET INFECTIOUS DISEASES

Measles investigation: A moving target

(2014) Megan R. Helmecke et al.   AMERICAN JOURNAL OF INFECTION CONTROL

U.S. Hospitalizations for Pneumonia after a Decade of Pneumococcal Vaccination

(2013) Marie R. Griffin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Serotype-Specific Changes in Invasive Pneumococcal Disease after Pneumococcal Conjugate Vaccine Introduction: A Pooled Analysis of Multiple Surveillance Sites

(2013) Daniel R. Feikin et al.   PLOS MEDICINE

Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50years

(2012) Derek Weycker et al.   VACCINE

A game dynamic model for vaccine skeptics and vaccine believers: Measles as an example

(2011) Eunha Shim et al.   JOURNAL OF THEORETICAL BIOLOGY

Behavioral Economics and Regulatory Analysis

(2011) Lisa A. Robinson et al.   RISK ANALYSIS

Healthcare utilization and cost of pneumococcal disease in the United States

(2011) Susan S. Huang et al.   VACCINE

Clinical and economic burden of pneumococcal disease in older US adults

(2010) Derek Weycker et al.   VACCINE

The mortality cost to smokers

(2008) W. Kip Viscusi et al.   JOURNAL OF HEALTH ECONOMICS